ReviewCancer management and research2026
Therapeutic Potential of Ion Carrier Antibiotics in Ovarian Cancer: Mechanisms and Prospects.
Review in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With over two-thirds of cases diagnosed at advanced stages, ovarian cancer is the deadliest gynecological cancer. In 70% of patients receiving standardized treatment, recurrence happens within 12-24 months, leading to a 5-year survival rate below 35%. Patients with ovarian cancer now have a better outlook thanks to personalized precision treatment; however, treating advanced ovarian cancer remains challenging. The poor 5-year survival rate and disease recurrence in individuals with ovarian cancer are mainly caused by platinum resistance. Therefore, targeted screening for drugs that can not only inhibit the growth of ovarian cancer cells but also control their migration, invasion, and drug resistance is especially important to reduce the treatment challenges of ovarian cancer. Ionic carrier antibiotics have enhanced the resistance of several malignant tumors to chemotherapy and have shown anti-tumor properties. This article explores the development of ionic carrier antibiotic research in ovarian cancer to evaluate their potential role in the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.